Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 302.12M P/E - EPS this Y 4.20% Ern Qtrly Grth -
Income -68.96M Forward P/E -3.24 EPS next Y -2.90% 50D Avg Chg 6.00%
Sales - PEG -0.05 EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.31 EPS next 5Y 23.10% 52W High Chg -63.00%
Recommedations 1.80 Quick Ratio 14.47 Shares Outstanding 51.44M 52W Low Chg 72.00%
Insider Own 2.95% ROA -19.17% Shares Float 41.01M Beta 1.64
Inst Own 102.13% ROE -29.24% Shares Shorted/Prior 2.78M/2.26M Price 6.60
Gross Margin - Profit Margin - Avg. Volume 340,114 Target Price 8.75
Oper. Margin - Earnings Date May 8 Volume 140,737 Change 0.00%
About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

PMV Pharmaceuticals, Inc. News
04/19/24 PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
07:00 AM PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
03/18/24 PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
03/01/24 PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
02/29/24 PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
02/26/24 PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
01/18/24 PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
01/05/24 PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
11/09/23 PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates
11/09/23 PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
10/16/23 PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10/12/23 PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
10/11/23 PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
10/06/23 Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?
09/21/23 We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate
09/20/23 PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08/30/23 Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
08/29/23 PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross
08/09/23 PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
06/06/23 PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
PMVP Chatroom

User Image moonbear Posted - 2 days ago

$PMVP Still under-the-radar with retail despite 97% tute ownership. Added to watchlist

User Image Hsons Posted - 4 days ago

$PMVP Rejected at 1.80 and 182 previously. Once cross this resistance this could easily see 3+

User Image talkingtrades Posted - 4 days ago

$PMVP the time is coming!!!

User Image maizeblue22 Posted - 1 week ago

$PMVP continue to climb

User Image Hsons Posted - 1 week ago

$PMVP Analyst Minimum price target is 5.0 with new coverage from Jeffries and pt 5

User Image StockInvest_us Posted - 2 weeks ago

Signal alert: $PMVP - Double Bottom https://stockinvest.us/l/mRrm0WxWGr

User Image SomeRandomDude01 Posted - 2 weeks ago

$PMVP Serious potential πŸ‘

User Image G101SPM Posted - 1 month ago

$PMVP $1.70 bid. DAC $1.635. EXIT $4.00. NEWS: PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors.

User Image DekmarTrades Posted - 1 month ago

HIGH ALERT! Hot 8am PRs: $SVRE $PMVP $VRWD $PVCT $MDT $CMGR

User Image Stock_Titan Posted - 1 month ago

$PMVP PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors https://www.stocktitan.net/news/PMVP/pmv-pharmaceuticals-announces-first-patient-dosed-in-global-tumor-14u1bj1j57lq.html

User Image G101SPM Posted - 1 month ago

$PMVP $1.73 bid. DAC (2) 1.65 last $1.54 (2.16.24). EXIT $4.00. UPDATE: PC14586 ( anti-tumor activity of rezatapopt in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation) registrational Phase 2 clinical trial remains on track to initiate in Q1 2024.

User Image OpenOutcrier Posted - 1 month ago

$PMVP (+7.8% pre) PMV Pharmaceuticals (PMVP) PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO - SI https://ooc.bz/l/28003

User Image Stock_Titan Posted - 1 month ago

$PMVP PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer https://www.stocktitan.net/news/PMVP/pmv-pharmaceuticals-pynnacle-phase-i-data-of-rezatapopt-in-advanced-enzcw64wj8nj.html

User Image Lukey63 Posted - 1 month ago

$PMVP Dirt cheap stock trading at 1/3 of cash and TBV and a cash runway that looks to be into 2027. Worth the risk IMO.

User Image c00lmike Posted - 1 month ago

https://youtube.com/watch?v=53VauuoS8ZQ&si=j9Clp3BsLS76S1GB $PMVP

User Image Stock_Titan Posted - 02/29/24

$PMVP PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights https://www.stocktitan.net/news/PMVP/pmv-pharmaceuticals-reports-full-year-2023-financial-results-and-pjy3y6yuhzcv.html

User Image StockInvest_us Posted - 02/28/24

Signal alert: $PMVP - PivotPoint bottom https://stockinvest.us/l/AFGaxej6kH

User Image Ninja_Tradez Posted - 2 months ago

πŸ“’ $PMVP - PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference https://newsfilter.io/a/105184b66890cbc6b67bab39484c99f9

User Image Stock_Titan Posted - 2 months ago

$PMVP PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference https://www.stocktitan.net/news/PMVP/pmv-pharmaceuticals-to-participate-in-the-td-cowen-44th-annual-dp8ydb7abm47.html

User Image rojorojo Posted - 2 months ago

$PMVP In with 2 shares at $1.70 each since January 25th and waiting, waiting.... for an increase. Have two limit sells in place, one for $8.50 and the other for $9.75.

User Image G101SPM Posted - 2 months ago

$PMVP $1.54 ask. BUY/ADD TO LONG POSITION. DAC (dollar average cost) (2) $1.635 prior $1.73 (12.23.23). Set EXIT at $4.00 with SPM 81.12 tag as review value. OVERVIEW: (1) Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%, (2) Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026; (3) PC14586 registrational Phase 2 clinical trial remains on track to initiate in 1Q24; (4) Held by Institutions 104%. Short % of true float (2.15.24) 2.9% on 41.83 M.

User Image Souldrops07 Posted - 2 months ago

Hi guys.. keep your eyes open to $Acet , $GTHX , $RIGL , $PMVP , $IMUX To be honest I have a position in all. See you later πŸ‘‹

User Image rojorojo Posted - 2 months ago

@TheLearnerEarner @TheLearnerEarner Hello! Any updated thoughts on this stock? Thanks $PMVP

User Image Souldrops07 Posted - 2 months ago

$PMVP Hi guys.. keep your eyes on.. see you later πŸ’°πŸ’°

User Image Stockboi_ Posted - 2 months ago

$SING $NAAS $PMVP interesting charts

User Image TheLearnerEarner Posted - 2 months ago

$PMVP looking good today πŸ“‹

User Image TheLearnerEarner Posted - 01/30/24

$PMVP be ready to move upwards on the staircase πŸ“ˆ

User Image TheLearnerEarner Posted - 01/29/24

$PMVP staircase on the 5 minute chart, breaking out πŸ“‹

User Image TheLearnerEarner Posted - 01/29/24

$PMVP moving upwards, slowly but surely πŸ“‹

User Image elbowcrooker Posted - 3 months ago

$PMVP starting a position here.

Analyst Ratings
Jefferies Buy Apr 12, 24
HC Wainwright & Co. Buy Mar 7, 24
Ladenburg Thalmann Buy Dec 27, 23
HC Wainwright & Co. Buy Oct 16, 23
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy May 17, 23
Oppenheimer Outperform May 11, 23
HC Wainwright & Co. Buy Mar 20, 23
Oppenheimer Outperform Mar 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ORBIMED ADVISORS LLC 10% Owner 10% Owner Nov 22 Sell 2.23 87,786 195,763 11/24/23
Mack David Henry President and CEO President and CEO Aug 07 Option 0.53 85,500 45,315 165,470 08/08/23
Mack David Henry President and CEO President and CEO Apr 27 Option 0.53 33,000 17,490 79,970 04/29/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Mar 29 Sell 21.69 474,500 10,291,905 03/31/22
Mack David Henry President and CEO President and CEO Dec 15 Option 0.53 9,000 4,770 26,970 12/16/21